Zealand Pharma

444

DKK

+2.59 %

Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+2.59%

-19.71%

-41.58%

-37.95%

-46.18%

-28.62%

+470.33%

+90.89%

+458.49%

Zealand Pharma is a biotechnology company. Particular focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest business is in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Söborg, Denmark.

Market cap

31.55B DKK

Turnover

55.45M DKK

Revenue

62.69M

EBIT %

-2,029.37 %

P/E

-

Dividend yield-%

-

Financial calendar

8/5

2025

Interim report Q1'25

14/8

2025

Interim report Q2'25

13/11

2025

Interim report Q3'25

All

Press releases

ShowingAll content types

Press release4/24/2025, 5:00 AM

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

Press release4/23/2025, 1:00 PM

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Regulatory press release4/19/2025, 8:05 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release4/19/2025, 8:00 PM

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

Regulatory press release3/31/2025, 9:00 PM

Total number of shares and voting rights in Zealand Pharma as of March 31, 2025

Regulatory press release3/27/2025, 5:20 PM

Resolutions from Zealand Pharma's Annual General Meeting 2025

Regulatory press release3/25/2025, 4:00 PM

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Regulatory press release3/20/2025, 4:00 PM

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Press release3/17/2025, 7:00 AM

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Regulatory press release3/12/2025, 6:00 AM

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity

Regulatory press release2/20/2025, 12:00 PM

Zealand Pharma convenes its Annual General Meeting 2025

Regulatory press release2/20/2025, 9:08 AM

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024

Regulatory press release2/20/2025, 6:00 AM

Zealand Pharma Announces Financial Results for the Full Year 2024

Press release2/13/2025, 4:00 PM

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Press release1/7/2025, 4:00 PM

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Press release1/6/2025, 4:00 PM

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Regulatory press release12/25/2024, 4:40 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Regulatory press release12/25/2024, 4:30 PM

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Regulatory press release12/19/2024, 7:58 PM

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Press release12/10/2024, 2:00 PM

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.